Aexon Labs Inc. has identified dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives acting as orexin receptors agonists. As such, they are reported to be possibly useful for the treatment of Parkinson’s disease, and type 1 and type 2 narcolepsy.
Accutar Biotechnology Inc. has patented new substituted quinoline derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.
Concerto Bioscience Inc. has received FDA clearance of its IND application to initiate a first-in-human phase I trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product to treat atopic dermatitis.
Researchers at The Scripps Research Institute and the IAVI Neutralizing Antibody Center are developing a novel experimental vaccine targeting the germline to stimulate precursor B cells and produce broadly neutralizing antibodies (bnAbs) against the membrane-proximal external region (MPER) of the gp41 protein found in the HIV-1 envelope.
Monte Rosa Therapeutics Inc. has submitted an IND application to the FDA for MRT-6160, a highly selective and orally bioavailable molecular glue degrader directed against VAV1 in development for systemic and neurological autoimmune diseases.
Signal transducer and activator of transcription 3 (STAT3) plays a key role in cell proliferation observed in colorectal cancer (CRC), where up-regulation of STAT3 accelerates tumorigenesis and promotes metastasis.
Resolution Therapeutics Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of its lead candidate RTX-001 in patients with decompensated liver cirrhosis.
RSS
